XWARPTG
Market cap41mUSD
Dec 23, Last price
36.70PLN
1D
-3.42%
1Q
-32.29%
IPO
-41.19%
Name
Poltreg SA
Chart & Performance
P/E
—
P/S
122.34
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.96%
Rev. gr., 5y
%
Revenues
1m
+40.04%
Net income
-14m
L
CFO
-13m
L+54.43%
Profile
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 1,399 40.04% | 999 -9.10% | 1,099 57.00% | |||
Cost of revenue | 7,163 | 4,627 | 2,753 | |||
Unusual Expense (Income) | ||||||
NOPBT | (5,764) | (3,628) | (1,654) | |||
NOPBT Margin | ||||||
Operating Taxes | (3,265) | 41 | ||||
Tax Rate | ||||||
NOPAT | (5,764) | (363) | (1,695) | |||
Net income | (13,551) -1,143.99% | 1,298 -134.35% | (3,779) 284.83% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 93,914 | |||||
BB yield | -39.97% | |||||
| Debt | ||||||
Debt current | 393 | 36 | 142 | |||
Long-term debt | 15,995 | 15,753 | 187 | |||
Deferred revenue | 12,498 | |||||
Other long-term liabilities | 798 | 629 | 400 | |||
Net debt | (49,563) | (74,311) | (103,612) | |||
| Cash flow | ||||||
Cash from operating activities | (13,284) | (8,602) | (3,837) | |||
CAPEX | (31,572) | (7,583) | (2,967) | |||
Cash from investing activities | (31,572) | (5,049) | (454) | |||
Cash from financing activities | 20,771 | (254) | 93,182 | |||
FCF | (36,890) | (21,085) | (3,114) | |||
| Balance | ||||||
Cash | 65,951 | 90,036 | 103,941 | |||
Long term investments | 64 | |||||
Excess cash | 65,881 | 90,050 | 103,886 | |||
Stockholders' equity | (25,242) | (11,691) | (9,724) | |||
Invested Capital | 134,249 | 121,261 | 113,311 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 4,663 | 4,663 | 3,415 | |||
Price | 49.80 8.26% | 46.00 -33.14% | 68.80 | |||
Market cap | 232,217 8.26% | 214,498 -8.71% | 234,952 | |||
EV | 182,654 | 140,187 | 131,340 | |||
EBITDA | (4,713) | (2,805) | (1,079) | |||
EV/EBITDA | ||||||
Interest | 356 | 284 | 41 | |||
Interest/NOPBT | ||||||